535 related articles for article (PubMed ID: 29763622)
1. A Convergence-Based Framework for Cancer Drug Resistance.
Konieczkowski DJ; Johannessen CM; Garraway LA
Cancer Cell; 2018 May; 33(5):801-815. PubMed ID: 29763622
[TBL] [Abstract][Full Text] [Related]
2. Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy.
Wu D; Wang DC; Cheng Y; Qian M; Zhang M; Shen Q; Wang X
Semin Cancer Biol; 2017 Feb; 42():13-19. PubMed ID: 27840278
[TBL] [Abstract][Full Text] [Related]
3. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.
Sabnis AJ; Bivona TG
Trends Mol Med; 2019 Mar; 25(3):185-197. PubMed ID: 30686761
[TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to cancer immunotherapy.
Draghi A; Chamberlain CA; Furness A; Donia M
Semin Immunopathol; 2019 Jan; 41(1):31-40. PubMed ID: 29968044
[TBL] [Abstract][Full Text] [Related]
5. Towards defining biomarkers indicating resistances to targeted therapies.
Stehle F; Schulz K; Seliger B
Biochim Biophys Acta; 2014 May; 1844(5):909-16. PubMed ID: 24269379
[TBL] [Abstract][Full Text] [Related]
6. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.
Schram AM; Chang MT; Jonsson P; Drilon A
Nat Rev Clin Oncol; 2017 Dec; 14(12):735-748. PubMed ID: 28857077
[TBL] [Abstract][Full Text] [Related]
7. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
Wijdeven RH; Pang B; Assaraf YG; Neefjes J
Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
[TBL] [Abstract][Full Text] [Related]
8. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.
Zhai Z; Yu X; Yang B; Zhang Y; Zhang L; Li X; Sun H
Semin Cell Dev Biol; 2017 Apr; 64():107-115. PubMed ID: 27578007
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in cancer.
Tsimberidou AM
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance to targeted therapies: déjà vu all over again.
Groenendijk FH; Bernards R
Mol Oncol; 2014 Sep; 8(6):1067-83. PubMed ID: 24910388
[TBL] [Abstract][Full Text] [Related]
12. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
Bottsford-Miller JN; Coleman RL; Sood AK
J Clin Oncol; 2012 Nov; 30(32):4026-34. PubMed ID: 23008289
[TBL] [Abstract][Full Text] [Related]
13. Strategies in functional proteomics: Unveiling the pathways to precision oncology.
Favicchio R; Thepaut C; Zhang H; Arends R; Stebbing J; Giamas G
Cancer Lett; 2016 Nov; 382(1):86-94. PubMed ID: 26850375
[TBL] [Abstract][Full Text] [Related]
14. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.
Collins DC; Sundar R; Lim JSJ; Yap TA
Trends Pharmacol Sci; 2017 Jan; 38(1):25-40. PubMed ID: 27871777
[TBL] [Abstract][Full Text] [Related]
15. Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics.
Comment LA; Ward AF; Schrock AB; Fabrizio D; Venstrom JM; Hegde PS; Alexander BM
Clin Pharmacol Ther; 2020 Sep; 108(3):440-443. PubMed ID: 32744335
[No Abstract] [Full Text] [Related]
16. Targeting of the AKT/m-TOR Pathway: Biomarkers of Resistance to Cancer Therapy--
AKT/m-TOR Pathway and Resistance to Cancer Therapy.
Spirina LV; Kondakova IV; Tarasenko NV; Slonimskaya EM; Usynin EA; Gorbunov AK; Yurmazov ZA; Chigevskaya SY
Zhongguo Fei Ai Za Zhi; 2018 Jan; 21(1):63-66. PubMed ID: 29357975
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment and cancer therapy resistance.
Sun Y
Cancer Lett; 2016 Sep; 380(1):205-15. PubMed ID: 26272180
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies.
Aldea M; Andre F; Marabelle A; Dogan S; Barlesi F; Soria JC
Cancer Discov; 2021 Apr; 11(4):874-899. PubMed ID: 33811122
[TBL] [Abstract][Full Text] [Related]
19. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.
Meric-Bernstam F; Johnson AM; Dumbrava EEI; Raghav K; Balaji K; Bhatt M; Murthy RK; Rodon J; Piha-Paul SA
Clin Cancer Res; 2019 Apr; 25(7):2033-2041. PubMed ID: 30442682
[TBL] [Abstract][Full Text] [Related]
20. Anticipating designer drug-resistant cancer cells.
Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
